How should I transition from Vyvanse (lisdexamfetamine) to Concerta (extended‑release methylphenidate)?

How to Switch from Vyvanse to Concerta

You can directly switch from Vyvanse (lisdexamfetamine) to Concerta (methylphenidate ER) without a washout period, starting Concerta the day after stopping Vyvanse, using dose conversion guidelines based on clinical judgment rather than strict equivalency ratios.

Switching Strategy

Immediate Transition Approach

Stop Vyvanse and start Concerta the following morning. No tapering or washout period is required when switching between stimulant classes (amphetamine to methylphenidate), as both have short half-lives and are cleared within 24 hours 1.

Dose Conversion Guidelines

The FDA label for Concerta does not provide direct conversion from lisdexamfetamine, stating only that "clinical judgment should be used when selecting the starting dose" for patients on other stimulant regimens 1. However, you can use the following practical approach:

Starting Concerta doses based on prior Vyvanse dose:

• Vyvanse 20-30 mg → Start Concerta 18-27 mg once daily
• Vyvanse 40-50 mg → Start Concerta 36 mg once daily
• Vyvanse 60-70 mg → Start Concerta 54-72 mg once daily

These conversions are conservative estimates. Research shows that 41% of patients switching between stimulant families require dose adjustments due to tolerability issues, and this cannot be predicted by baseline characteristics 2.

Titration After the Switch

Start lower rather than higher. If you're uncertain about the equivalent dose, begin with 18 mg (for children/adolescents) or 18-36 mg (for adults) regardless of prior Vyvanse dose, then titrate up 1.

• Increase in 18 mg increments at weekly intervals if response is inadequate
• Maximum doses: 54 mg/day (children 6-12 years), 72 mg/day (adolescents and adults, not to exceed 2 mg/kg/day in adolescents) 1
• Monitor response using standardized rating scales at each visit

Important caveat: Studies show that more than 43% of patients switching to Concerta require higher-than-equivalent doses for successful transition, and some need supplemental immediate-release methylphenidate for breakthrough symptoms 3.

Monitoring the Switch

First 2-4 Weeks Post-Switch

Assess weekly (by visit or phone) for:

• Efficacy: ADHD symptom control compared to baseline on Vyvanse
• Tolerability: Common side effects include decreased appetite (most common), insomnia, irritability, and mood changes 4
• Duration of coverage: Concerta provides approximately 12 hours of coverage; Vyvanse provides up to 13 hours 5. If evening symptom breakthrough occurs, consider adding immediate-release methylphenidate 5-10 mg in late afternoon 3

What to Expect

Success rates: Research indicates that switching from amphetamine products (like Vyvanse) to methylphenidate products (like Concerta) is common in clinical practice. In one study, 41% of patients required switching from their initial stimulant family within 90 days due to poor tolerability 2. Another study found that among children switching to lisdexamfetamine, 41.3% continued treatment for a year or longer 4.

Side effect profile: Methylphenidate and amphetamine products have similar adverse effect profiles, though individual patients may tolerate one better than the other. The most common side effects with Concerta mirror those of Vyvanse: decreased appetite, insomnia, irritability, and weight loss 6, 4.

When the Switch Fails

If inadequate response or prohibitive side effects occur after 4 weeks of appropriate dose titration:

1. Consider switching back to an amphetamine product (approximately 70% respond to either methylphenidate or amphetamine alone; nearly 90% respond if both are tried) 6
2. Add immediate-release methylphenidate to Concerta if the issue is duration of coverage rather than efficacy 3
3. Consider non-stimulant alternatives (atomoxetine, guanfacine, clonidine) if both stimulant families fail

Critical Pitfalls to Avoid

• Don't assume 1:1 dose equivalency exists between Vyvanse and Concerta—there is no validated conversion ratio
• Don't crush, chew, or divide Concerta tablets—this destroys the extended-release mechanism 1
• Don't forget cardiac screening before initiating any stimulant, including when switching (assess personal/family history of sudden death, arrhythmia, cardiac disease) 1
• Don't overlook substance use risk in adolescents and adults—assess for diversion risk and consider prescribing smaller quantities initially 7
• Don't continue ineffective treatment—if no improvement after one month of appropriate dosing, discontinue and try alternatives 1

Special Populations

Preschool children (4-5 years): Methylphenidate is preferred over amphetamines in this age group based on available evidence, though use remains off-label 7.

Adolescents and adults: Screen for substance use before switching. Both Vyvanse and Concerta have abuse potential, though lisdexamfetamine's prodrug formulation theoretically reduces this risk 5. Monitor for diversion 7.